Concepedia

Mark S. Albom

MS

Statistics

Publications

30

Citations

1.4K

H-Index

22

Active since

2003

Affiliations

Avalon Pharma (United States)(Current)

Teva Pharmaceuticals (United States)

Brandywine Photonics (United States)

Worldwide Clinical Trials (United States)

Mark S. Albom is an author at Avalon Pharma (United States) specializing in pharmacology, drug discovery, and medicinal chemistry.

Publications per year

2003–2016

30

Publications

30

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Bruce Ruggeri, Diane E. Gingrich, Thelma S. Angeles et al. · PubMed · 2003 · 124 citations

, , +15

Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells

Weihua Wan, Mark S. Albom, Lihui Lü et al. · Blood · 2005 · 105 citations

, , +11

Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis

Rabindranath Tripathy, Alyssa Reiboldt, Patricia A. Messina et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 105 citations · Full text

, , +16

1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors

Rabindranath Tripathy, Arup K. Ghose, Edward R. Bacon et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 91 citations · Full text

, , +11

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)

Gregory R. Ott, Mangeng Cheng, Keith S. Learn et al. · Journal of Medicinal Chemistry · 2016 · 90 citations · Full text

, , +17

1–5 of 30